BOSTON, July 14 — A new chapter in the fight against cancer is unfolding, and it involves editing a patient’s own immune cells with a technology that won a Nobel Prize. CRISPR Therapeutics, co-founded by Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna, has reported an 83% remission rate from its clinical trial for CTX-112, a next-generation cell therapy. In plain terms, think of it like giving a security guard a precise wanted poster.
The therapy takes a patient’s T cells — the body’s frontline immune soldiers — and re-engineers them to recognize and attack cancer. This is the core idea behind CAR-T cell therapy, a field that has been building for decades.
The practical upshot for patients is a potentially powerful new weapon against blood cancers.
From a Lab Idea to a Living Drug
The story of CAR-T therapy starts long before the CRISPR era. Dr. Zelig Eshhar at the Weizmann Institute of Science in Israel first described chimeric antigen receptors in 1989. That was the blueprint.
The first real-world success came in 2010, when Dr. Carl June at the University of Pennsylvania treated three patients with chronic lymphocytic leukemia. His team published results in 2011 showing that two of those three patients achieved remission.
Then came a case that changed everything. In 2012, a landmark study led by Dr. Stephan Grupp at Children’s Hospital of Philadelphia treated a pediatric patient named Emily Whitehead. She became the first child to receive CAR-T therapy and, as of 2024, remains cancer-free.
That success spurred a wave of development. Novartis acquired the rights to Kymriah in 2012 and received FDA approval in 2017.
That same year, Kite Pharma, a Gilead subsidiary, won approval for Yescarta. Other major players have since entered the field, including Bristol Myers Squibb with Breyanzi and Johnson & Johnson with Carvykti.
What CRISPR Brings to the Table
CRISPR Therapeutics, co-founded by Charpentier and Doudna — who won the 2020 Nobel Prize in Chemistry for the CRISPR-Cas9 gene-editing tool — began clinical trials for its own candidate, CTX-112, in 2022. The company reported its 83% remission rate in June 2024. The global market for these therapies is growing fast.
The CAR-T market was valued at $3.8 billion in 2023 and is projected to reach $15.2 billion by 2030. That growth reflects both the medical promise and the commercial interest in a field that has already produced several approved drugs.
The science is still evolving. Researchers are working to make these treatments more effective against solid tumors and to reduce side effects. But the core idea remains the same: reprogram the immune system to do what it was designed to do, only better. Consult your doctor for medical advice.
